FORM 51-102F3
MATERIAL CHANGE REPORT

Item 1: Name and Address of Reporting Issuer

Advanced Proteome Therapeutics Corporation (the "**Company**" or "**APC**")
BioSquare, 650 Albany Street, Suite 113
Boston, Massachusetts 02118

Item 2: Date of Material Change

March 21, 2019.

Item 3: News Release

A news release was issued and disseminated on February 19, 2019 and filed on SEDAR (www.sedar.com).

Item 4: Summary of Material Changes

The Company received the approval from the TSX Venture Exchange ("**TSXV**") on March 21, 2019 to settle debt in the amount of $11,449.15 by the issuance of 228,983 shares at $0.05 per share.

Item 5: Full Description of Material Change

The Company received the approval from the TSXV on March 21, 2019 to settle debt in the amount of $11,449.15 by the issuance of 228,983 shares at a price of $0.05 per share to one creditor.

Item 6: Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

Not applicable.

Item 7: Omitted Information

None.

Item 8: Executive Officer

Paul Woodward
President and CEO
T: 604.690.3797

Item 9: Date of Report

March 22, 2019.